AI Article Synopsis
- Belinostat therapy, combined with hematopoietic stem cell transplantation, shows promise for patients with difficult-to-treat peripheral T-cell lymphoma.
- The treatment is particularly effective for patients who have experienced multiple relapses and refractory cases in their illness.
- A specific case demonstrated that belinostat helped achieve a lasting complete hematologic response for over 21 months after the transplant.
Article Abstract
Key Clinical Message: Belinostat therapy followed by hematopoietic stem cell transplantation is a promising salvage strategy for heavily pretreated patients with peripheral T-cell lymphoma.
Abstract: Effective treatments for peripheral T-cell lymphoma in the relapsed and refractory (r/r) setting are limited. However, with the development and approval of innovative therapies, effective therapeutic options are becoming available for this patient population. This case report describes the treatment course of a patient with multiple r/r nodal follicular T-helper cell lymphoma of angioimmunoblastic type. Treatment with the histone deacetylase inhibitor belinostat as bridging, enabled allogeneic stem cell transplantation and resulted in a durable complete hematologic response for at least 21 months post-transplantation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228349 | PMC |
| http://dx.doi.org/10.1002/ccr3.9159 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!